Spots Global Cancer Trial Database for A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Official Title: A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Study ID: NCT01106508
Interventions
Study Description
Brief Summary: This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Novartis Investigative Site, Utrecht, , Netherlands
Novartis Investigative Site, Zürich, , Switzerland
Novartis Investigative Site, Oxford, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
